Alterity Therapeutics to Present New Data on ATH434 at the

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...

Related Keywords

Colorado ,United States ,Melbourne ,Victoria ,Australia ,Boston ,Massachusetts ,San Francisco ,California ,Denver ,American ,Americans ,Remy Bernarda ,Danielo Claassen ,Margaret Bradbury ,David Stamler ,Daniel Claassen ,Hannah Howlett ,Department Of Pharmaceutical Sciences ,Nonclinical Development ,European Commission ,Alterity Therapeutics ,Nasdaq ,World Orphan Drug Congress United States ,American Academy Of Neurology ,Wayne State University ,National Institute Of Health ,Vanderbilt University Medical Center ,Parkinson Foundation ,Unique Iron Targeting Drug ,Treating Friedreich ,Pharmaceutical Sciences ,Wayne State ,American Academy ,Novel Inhibitor ,Synuclein Aggregation ,Multiple System Atrophy ,Chief Executive Officer ,Plight Chain ,Clinical Progression ,Early Multiple System ,Vanderbilt University Medical ,Clinical Phase Small Molecule ,Moderate Affinity ,Disease Model ,Vice President ,System Atrophy ,Mouse Model ,National Institute ,Neurological Disorders ,Disease Information Page ,Multiple System ,Media Contacts ,Securities Act ,Australian Stock Exchange Ath Ax ,Alterity Therapeutics Limited ,Conference ,Preclinical Research ,